SMS Pharma sells unit to Mylan Lab for Rs 173 crore

Published: 19th October 2012 01:15 PM  |   Last Updated: 19th October 2012 01:15 PM   |  A+A-

Hyderabad-based SMS Pharmaceuticals  has sold its manufacturing unit in Visakhapatnam to Mylan Laboratories for over Rs 173 crore. The unit manufactures bulk drugs and formulations in the oncology segment and is yet to get an approval from the US Food and Drugs Administrator. The proceeds from the sale of the production unit is expectd to help SMS Pharma to stregnthen its existing facilities and reduce fiscal overheads. For Mylan, this will be the second acquisition in India. In the past, it acquired 71.5% stake in Hyderabad-based active pharmaceutical ingredients maker Matrix Laboratories for over $736 million. According to SMS Pharma, the sale will not have much impact on its revenues and will create a path for strategic alliances with the multinationalas well as business development by way of getting multiple products.  Owing to high cost of funds, SMS Pharma has slipped into the red over the the past few quarters.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp